# Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

Source: https://onco.cc/trials/nct04489420/  
OnCo record `nct04489420` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CYNK-001 run by Celularity Incorporated, terminated.

## Summary

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM is a phase 1 interventional study registered as NCT04489420 by Celularity Incorporated, with 3 participants enrolled, started 2020-10-01. Conditions recorded: Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Molecular Mechanisms of Pharmacological Action, Antiviral Agents, Anti-infective Agents, Analgesics, Non-narcotic, Analgesics, Sensory System Agents and Peripheral Nervous System Agents. Interventions recorded: CYNK001-IV and CYNK001-IT.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04489420
- Phase: 1
- Setting: A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Recurrent Glioblastoma Multiforme (GBM)
- Sponsor: Celularity Incorporated
- Enrolled: 3

## Sources

- ClinicalTrials.gov NCT04489420: https://clinicaltrials.gov/study/NCT04489420

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [CYNK-001](https://onco.cc/drugs/cynk-001/)
- companies: [Celularity](https://onco.cc/companies/celularity/)

---
JSON: https://onco.cc/api/v1/entities/nct04489420.json